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Background: Cimicoxib is a new coxib anti-inflammatory drug for use in the dog. To determine a preclinical
dosage regimen for cimicoxib in dog, a reversible model of kaolin–induced paw inflammation was used.
Dosage regimens were established using pharmacokinetic/pharmacodynamic (PK/PD) modeling approach
(indirect response model).
Results: Analgesic, anti-inflammatory and antipyretic endpoints investigated with the inflammation model
established the efficacy of cimicoxib at a dose of 2 mg/kg administered orally (single dose) in 12 beagle dogs.
For both the oral and IV route of administration two groups of dogs to be identified namely Poor Metabolizers
(PM) and Extensive Metabolizers (EM).The terminal half-life after oral administration was 8.0 ± 0.6 h for the PM and
4.6 ± 2.6 h for the EM groups, with the corresponding values after the IV route being 5.6 ± 1.7 h and 2.7 ± 0.9 h
(mean ± SD).
The main pharmacodynamic parameters (potency, efficacy, and sensitivity) were estimated for four endpoints
(body temperature, creeping speed, ground vertical reaction force and clinical lameness score). The plasma
concentration corresponding to half the maximum of the indirect effect were 239 μg/L for creeping speed,
284 μg/L for the lameness score, 161 μg/L for the ground reaction vertical force and 193 μg/L for the body
temperature.
To document possible polymorphism of the cimicoxib disposition in the target dog population, cimicoxib was
administered by the intravenous route to 40 dogs (four different sized breeds). The cimicoxib half-lives in these
40 dogs were of same order of the magnitude as those of the EM beagle dogs. Thus pharmacokinetic and
pharmacodynamic parameters obtained from the EM beagle dogs were selected to simulate the dose-effect
relationship of cimicoxib after an oral administration allowing a dosage regimen to be selected for confirmation
by a clinical trial.
Conclusions: Cimicoxib was an efficacious anti-inflammatory, antipyretic and analgesic drug and a dosage
regimen of 2 mg/kg daily was determined for confirmatory clinical trials.
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Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) consti-
tute an essential therapeutic class both in human and
veterinary medicines. It is now well established that most
side effects of NSAIDs are related to their anti-cyclooxy-
genase-1 (anti-COX-1) activity while the therapeutic
effects are mainly associated with COX-2 inhibition. This
has led to the development of preferential or selective
COX-2 inhibitors among which are the diarylimidazol
derivatives (COXIB class) in an attempt to overcome the
side effects especially those of the gastro-intestinal tract
(g.i.t). One of these substances was recently developed for
therapeutic use in dogs: cimicoxib which is a sulfonamide,
like celecoxib, mavacoxib and firocoxib. High in vitro
potency of cimicoxib was measured for COX-2 inhibition
using a human whole blood assay (half maximal Inhibitory
Concentration (IC50) 66nM or 25 ng/mL). In vivo effects
were demonstrated in rats in adjuvant-induced arthritis,
and in air pouch and hyperalgesia models [1]. In fact, the
COXIB class is not homogenous regarding the COX-1/
COX-2 selectivity and some of its members such as
deracoxib and mavacoxib are classified as preferential and
moderately selective COX-2 inhibitors while others like
firocoxib and robenacoxib are classified as highly selective
COX-2 inhibitors with a more than 100-fold greater
potency for COX-2 inhibition and with little or no in vivo
inhibition of COX-1 [2]. Usually, with highly selective
COXIB compounds, no gastro intestinal tract (g.i.t) ulcer-
ation or antiplatelet effects are expected even at a max-
imum plasma concentration while significant COX-1
inhibition may occur with preferential COXIBs [2]. For
example, for deracoxib, the COX-1/COX-2 selectivity
index (using a whole blood assay and expressing results as
the ratio of IC50) was about 50–60 [3] and gastric ulcera-
tions were reported following some overdosing of dera-
coxib or as a result of its association with other substances
such as other NSAIDs or corticosteroids [4,5]. This means
that a COX-1/COX-2 selectivity index of 50 is not enough
to guarantee a margin of g.i.t safety and more highly
selective COXIBs are desirable. This is the case of
firocoxib with a selectivity index of 384 in a whole blood
assay [6] and for which a favorable tolerability was shown
in a large scale survey with a withdrawal rate associated
with g.i.t side effects as low as 2.9% of dogs (mainly
vomiting) and no serious drug-related adverse events [7].
However it was shown that firocoxib was able to slow
down wound healing in a canine gastric mucosal injury
model but by a mechanism independent of prostaglandin
synthesis [8] meaning that a high COX-1/COX2 selectivity
is not the only pharmacodynamic (PD) endpoint to con-
sider when discussing NSAID g.i.t tolerability. Another
factor of COXIB tolerability is the selected dosage
regimen; a dosage regimen depends on two pharma-
cokinetic (PK) parameters (namely plasma clearance andbioavailability for the extravascular route of administra-
tion) and of one PD parameter (namely the efficacious
plasma concentration that reflects the drug potency). In
addition, the dosage interval should also be rationally
determined according to the plasma terminal half-life
(which itself depends on plasma clearance and volume of
distribution [9]). For the COXIB class, the plasma clear-
ances are very different among substances from a very low
clearance for mavacoxib (2.7 mL/kg/h) [10] to a rather
high clearance for robenacoxib (810 mL/kg/h) [11] and
firocoxib (462 ml/kg/h) [6] which explains the large differ-
ences in half-lives namely 17.3 days (beagle dogs) for
mavacoxib, 0.63 h (beagle dogs) for robenacoxib and 5.9 h
(mixed-breed dogs) for firocoxib. Such differences are
reflected into the dosage regimen (dose and dosing inter-
val), with mavacoxib marketed at 2 mg/kg at one month
intervals vs. 5 mg/kg daily for firocoxib and 1-2 mg/kg
daily for robenacoxib. It is expected that a very short half-
life of about 1 h cannot maintain steady plasma con-
centrations over the entire daily dosage interval while a
very long terminal half-life is ineluctably associated with a
minimal delay (about 3–4 times the duration of half-life)
to achieve steady state conditions. In addition a popula-
tion PK survey for mavacoxib in osteoarthritic dogs,
showed wide between-subject variability with a typical ter-
minal half-life (population mean) of 44 days, but for some
dogs (5% of the population) it exceeded 80 days with
extreme values up to 140 days. It was shown for mava-
coxib that the PK differed considerably between young
adult beagle dogs and the typical geriatric large-breed
osteoarthritic patient [12] indicating that considering only
preclinical PK in young beagle dogs can be very mislead-
ing when rationally determining a dosage regimen for a
COXIB. In the present paper this point was specifically
addressed for cimicoxib by investigating the PK profiles in
breeds other than beagle dogs.
The present study reports how the dosage regimen of
cimicoxib (Cimalgex ND) was established using PK/PD
concepts [13-22] and provides preliminary information
on the interbreed variability of cimicoxib PK.
Results
Study 1
The time course of cimicoxib plasma concentrations vs.
time (h) following oral administration is presented in
Figure 1. Visual inspection of the graph suggests the ex-
istence of two subgroups of dogs regarding the terminal
half-life, with 4 dogs having a long terminal half-life
(8.0 ± 0.6 h) while the 8 other dogs exhibited a short
terminal half-life (2.9 ± 0.9 h) p < 0.0001). Plasma terminal
half-life is a hybrid parameter controlled by plasma clear-
ance and volume of distribution and the difference in the
rate of elimination between the two groups of dogs was




































Figure 1 Individual plasma concentrations of cimicoxib (ng/mL) vs. time (h) after a single oral administration of cimicoxib (2 mg/kg)
in 12 beagle dogs. Visual inspection of the figure suggests the existence of 2 subgroups of dogs which were named “Poor Metabolizers”
(red dotted line) and “Extensive Metabolizers” (blue continuous line) (see the text for explanation). Pink squares were female dogs and blue
circles male dogs. Letters indicates names of dogs.
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verify this hypothesis, the PK parameters of cimicoxib
were also estimated for the same twelve dogs after a single
intravenous (IV) cimicoxib administration (Figure 2). The
main IV PK parameters are summarized in Table 1 and
showed a significant difference between the two groups of
dogs for cimicoxib half-life (2-fold) and clearance (3-fold)
while the volumes of distribution were not significantly
different (p > 0.05). By analogy to the terminology adopted
for celecoxib [23], another COXIB for which a bimodal
repartition of a beagle dog population was observed, we
designated the group of beagle dogs rapidly eliminating
cimicoxib as “Extensive Metabolizers (EM)” and the group
of dogs slowly eliminating cimicoxib as “Poor Metaboli-
zers (PM)”, even if the cimicoxib metabolism per se was
not directly investigated in the present experimentation.
For all clinical endpoints an improvement after cimi-
coxib administration was observed for the EM and the
PM dogs. For the six pharmacodynamics endpoints in-
vestigated (excepting the lameness score), the maximum
effect was expressed as a percentage of improvement, a
100% effect indicating that the measures returned to
control values (reference measure before inflammation)
and a 0% effect indicating a complete lack of effect of the
cimicoxib. For the clinical lameness score, the effects were
expressed using a score ranging from 0 (no lameness) to 5
(5 maximum lameness). For each endpoint, the amplitude
and duration of the maximum effect were described foreach of the two groups of dogs (Table 2). The maximum
effect on skin temperature could not be evaluated in the
Poor-elimination group because no plateau could be
observed, with the improvement increasing constantly for
this endpoint from 37% to 91%. For the other endpoints,
the maximal observed effect was similar for the two
groups of dogs but the duration of a sustained maximal
effect and the duration of the overall effect were systemat-
ically longer in the group of PM dogs (see Figure 3). The
overall maximal effects for the two groups of dogs were
86% for the body temperature, 66% for the ground
reaction vertical force and 76% for the creeping speed. In
contrast, the corresponding duration of effect for these
endpoints was systematically longer in the PM group
(from 25 to 28 h for the PM group vs. from 13 to 16 h for
the EM group) (see Table 2 for details). For the analgesic
effect of cimicoxib, it was observed that the tolerance
threshold to the heat-induced pain was increased above
those recorded under control conditions (i.e.100%) to
reach a maximum of 232 ± 45% for the EM group and
152 ± 53% for the PM group (Figure 4) which is indicative
of a cimicoxib analgesic effect that is not limited to an
anti-inflammatory effect (see Discussion).
Figure 5 shows the observed and fitted values of the four
modelled endpoints for a representative dog. The efficacy
and potency parameters obtained for the four modelled
pharmacodynamic endpoints are presented in Table 3.





































Figure 2 Individual plasma concentrations of cimicoxib (ng/mL) vs. time (h) after a single intravenous administration of cimicoxib
(2 mg/kg) in 12 beagle dogs. Visual inspection of the figure confirms what has been observed in Figure 1 with the existence of the same 2
subgroups of dogs named “Poor Metabolizers” (red dotted line) and “Extensive Metabolizers” (blue continuous line). Letters indicates names of dogs.
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similar, ranging from 325 ng/ml for the ground reaction
vertical force to 786 ng/ml for the lameness for the group
of PM dogs but from 161 to 284 ng/mL for the EM dogs
(p < 0.001).
The average PK and PD parameters obtained in the 8
dogs of the EM subgroup (see Discussion) were used to
simulate the plasma concentration profiles and the
effects predicted by the PK/PD model of different dosing
regimens of cimicoxib administered by the oral route
(from 0.1 to 8 mg/kg). For this simulation, a dose-
linearity of the PK parameters was assumed but after the
completion and submission of this work, we have had
access to an unpublished experimental trial showing that
the disposition of cimicoxib after an oral administration
was not linear for doses ranging from 1 to 4 mg/kg due
to the limited solubility of cimicoxib (Vetoquinol,Table 1 Pharmacokinetic parameters (mean ± SD) of cimicoxi
Parameters Extensive metabolizers
AUC (h.μg/L) 7202 ± 1814*
V (L/kg) 1.12 ± 0.203
HL (h) 2.72 ± 0.858*
CL (L/h/kg) 0.31 ± 0.118*
Data were analysed using non-compartmental approach; AUC: Area under the curv
*Difference were significant between the two groups p < 0.001 for HL and AUC andunpublished results); for a dose of 1 mg/kg, the plasma
concentrations were higher than expected (correspond-
ing to a dose of 1.46 mg/kg for our simulations) and
for the dose of 4 mg/kg, the plasma concentrations
were lower than expected corresponding to a dose of
3.18 mg/kg for our simulations; nevertheless the results of
the simulations assuming linearity are shown in Figure 6
because the conclusions that were drawn remained
unchanged. For rectal temperature, creeping speed, overall
clinical lameness score and ground reaction vertical force,
a nearly maximal effect of cimicoxib was predicted to
occur for doses of 1, 1.5, 2, and 3 mg/kg, respectively. For
higher cimicoxib doses, only the duration of the max-
imum effect was increased. However, considering ground
reaction vertical force, the magnitude of the simulated
effect increased at doses > 2 mg/kg; a dose of 2 mg/kg was
finally selected for confirmatory clinical trial and for thatb administered by the IV route at 2 mg/kg to 12 dogs





e; V: Volume of distribution; HL: Plasma half- life; Cl: plasma clearance.
p < 0.01 for the CL.
Table 2 Level and duration of maximum improvement for each endpoint describing the effects of the cimicoxib
(2 mg/kg) administered by the oral route in the 4 Poor Metabolizers (PM) and 8 Extensive Metabolizers (EM) dogs
Endpoint Maximum effect Duration of the maximal effect Total duration of the effect
PM EM PM EM PM EM
Body temperature 87 ± 9% 84 ± 8% 19.6 h (from 2.1 to 21.7) 7 h (from 2.1 to 9.1 h) 25 h 13 h
Paw circumference 15 ± 3% 14 ± 2% 7 h (from 4.2 to 11.2 h) 9 h (from 2.2 to 11.2 h) 20 h 15 h
Skin plantar temperature No plateau observed 38 ± 6% Could not be determined 7 h (from 2.3 to 9.3 h) 22 h 13 h
Creeping speed 77 ± 7% 76 ± 9% 11.1 h (from 4.2 to 15.3 h) 7 h (from 2.2 to 9.2 h) 25 h 15 h
Clinical lameness score 1 or 2 1 or 2 10.9 h (from 4.8 to 15.7 h) 8.8 h (from 2.8 to 16 h) not assessed not assessed
Vertical normalized force 67 ± 6% 68 ± 7% 11.1 h (from 4.5 to 15.5 h) 6.9 h (from 2.6 to 9.5 h) 28 h 16 h
Analgesia 162 ± 53% 232 ± 45% 8.8 h (from 2.9 to 11.8 h) 7 h (from 2.9 to 9.8 h) 23 h not assessed
For the body temperature, the paw circumference, the creeping speed, the vertical normalised force obtained with a force plate and the analgesic effect, the
maximal estimated effect was expressed as a percentage of control value, a 100% maximum effect indicating a return to control value (no kaolin challenge).
Analgesia was assessed by the paw withdrawal time to a heat stimulus and values higher than 100% indicate that there was an analgesic effect of cimicoxib
independent of its anti-inflammatory effect i.e. that the paw withdrawal time was longer after the cimicoxib administration than in control condition (no inflamma-
tion). For the lameness, the clinical score ranged from 0 (no lameness) to 5 (maximal lameness): a score of 1 corresponding to a slight lameness and a score of
2 to an obvious lameness. The duration of the effect (maximal or total) was directly obtained from raw data. Duration of total effect is the time when the effects
of cimicoxib observed are superior to the placebo. Duration of maximal effect is duration during which a steady maximal effect was observed. Values are
mean ± SD for the maximal effect and mean and range value for the duration of the maximum effect.
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to mitigate a permanent inflammatory stimulus ranged
between 10 to 15 h for rectal temperature, creeping test,
vertical ground reaction force and clinical lameness score,
with this duration being sufficient to provide satisfactory
clinical results (see Discussion).
Study 2
Figure 7 shows the average terminal slope of cimicoxib
after an oral administration of cimicoxib to 10 dogs be-
longing to four different breeds. The half-life was com-
puted and descriptive statistics are presented by breed in
Table 4. Mean values of plasma half-life were 2.7 h,
3.2 h, 3.9 h and 4.4 h for: cavalier King Charles, Anglo-
French Hounds, Pointers, Bernes Moutain respectively
(P < 0.001, ANOVA). The intra-breed variability of the
terminal half-life was similar in each breed, with a coeffi-
cient of variation of 20-25%.
Discussion
Cimicoxib is a new coxib marketed in veterinary medi-
cine and with a terminal half-life between 2 and 4 h; its
pharmacokinetic profile is intermediary between that of
robenacoxib (half-life of 1 h) and that of firocoxib (half-
life of 7 h). During this experiment in beagle dogs we
identified two subgroups of subjects: one group of dogs
eliminating cimicoxib from plasma at a rapid rate and a
second group of dogs having a three-fold lower plasma
clearance ; they were termed by others who observed the
same phenomenon for celecoxib [23] extensive metaboli-
zers (EM) and poor metabolizers (PM). The origin and
mechanism of these different elimination patterns of
cimicoxib were not investigated but are likely to be due to
polymorphism of the enzymes cytochrome P450 2D15
(CYP2D15) in dogs, which have been shown to beinvolved in the polymorphism of canine celecoxib metab-
olism [23]. For mavacoxib, broad variability in pharmaco-
kinetics was also observed within laboratory beagle dogs
with a typical half-life of 15–17 days while some of these
beagle dogs had a half-life >30 days. For mavacoxib it was
postulated that there was polymorphism of a transporter
involved in the biliary clearance even if different sub-
populations could not be detected [12]. No equivalent
information has been published for firocoxib. In the
present experiment, in order to select the most relevant
subpopulation of beagle dogs (EM or PM) regarding the
future target dog population we conducted a pilot study in
field conditions on four different dog breeds of different
body size (Anglo-French Hounds, Pointers, Cavalier King
Charles Spaniels and Bernese Mountain Dogs) and a
rather short terminal half-life (from 2-4 h) was observed
for the 40 dogs investigated and we decided that our
subpopulation of EM beagle dogs should be considered
for the PK/PD dosage regimen determination.
For PK/PD investigations, a reversible kaolin paw
inflammation model i.e. an ethically acceptable inflam-
mation model was used to determine the main PD para-
meters of cimicoxib for a set of clinically relevant
endpoints able to reflect the antipyretic, analgesic and
anti-inflammatory potential. This model has been vali-
dated in our hands and is fully described elsewhere [15].
For the current experiment, the duration of the cimi-
coxib effect was short enough to avoid having to model
the time development of inflammation as was required
for meloxicam using the same protocol [15]. In other
words, it was assumed that the natural progression of
the inflammation following a kaolin administration
(increasing then decreasing after a more-or-less well-
defined plateau phase) was not a relevant confounding












































Figure 3 Improvement of the clinical lameness score observed after an oral administration of cimicoxib vs.placebo in PM and EM
dogs. Improvement of the clinical lameness score was observed (mean score + SD) vs. time (h) after oral administration of cimicoxib at 2 mg/kg
(red squares) or placebo (blue circles) after induction of paw inflammation in the 8 Extensive metabolizer (EM) dogs (A) and in 4 Poor
metabolizer (PM) dogs (B). The same maximal effect was observed for the two groups of dogs but the duration of the effect was longer for the
PM than for the EM group reflecting the different cimicoxib disposition observed between these two groups of dogs (see Figure 1). 0 no
lameness; 1 slight lameness: barely perceptible throughout almost the whole observation period; 2 obvious lameness but the animal maintains its
limb on the ground; 3 moderate lameness, the animal rests the limb on the ground slightly; 4 severe lameness: the animal uses its limb (makes
contact with and/or skims the ground) but it does not put its weight on the limb; 5 maximum lameness: the animal refuses to move
(it remains sitting or lying down) and/or avoids putting limb on the ground at all.
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and paw withdrawal time still were altered in first 56 h
after kaolin administration (spontaneous improvement
was 50%, a 100% improvement meaning return to the
prekaolin administration condition). This model (inflam-
mation >24 h) used to test daily administration will be
preferred to model with short inflammation like sodium
urate crystal (inflammation <18 h); model used for robe-
nacoxib and firocoxib [24,25]. Using a classical PK/PD
modelling approach, the cimicoxib efficacy (expressed asa percentage of return to control values) and the cimi-
coxib potency (measured by the plasma EC50/IC50) were
determined. For the subgroup of EM, EC50/IC50 for
rectal temperature, creeping speed under a tunnel, verti-
cal ground reaction force and a clinical lameness, scores
were between 0.422 and 0.745 nmol/ml i.e. slightly lower
than those obtained for meloxicam that were between
0.553 and 1.439 nmol/mL using the same canine model
and the same investigated endpoints indicating that





























Figure 4 Time development of the analgesic effect after an
oral administration of cimicoxib at 2 mg/kg vs. placebo
administration in 8 extensive metabolizer dogs. Pain was
assessed using a hind paw thermal escape model in control
conditions (no inflammation) and after a kaolin injection in the paw.
The paw withdrawal time was measured in seconds and expressed
as a percentage; 100% is the control value without inflammation
and 0% (at time 0) is the control value after induction of
inflammation. Visual inspection of the figure shows that cimicoxib
can develop an analgesia that is higher than 100% i.e. that under
cimicoxib, the withdrawal time of the inflamed paw was longer than
in control condition without inflammation. This suggests that the
analgesic effect of cimicoxib is not only due to its anti-inflammatory
effect but also to an intrinsic analgesic property.
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Imax were similar for cimicoxib and meloxicam (from
70 to 100% for cimicoxib and from 80 to 100% for
meloxicam) indicating that both drugs can totally or
near totally suppress symptoms associated with the
kaolin inflammation (hyperthermia, lameness).
For the analgesic effect, it was shown that cimicoxib
has two types of effect: a so-called anti-hyperalgesic
effect (i.e. an increase in the pain tolerance threshold
which was abnormally lowered by the inflammation) and
also an increase to the pain tolerance threshold beyond
that recorded during the control (placebo) period sug-
gesting a mechanism of cimicoxib action independent
from its anti-inflammatory effect. A similar observation
has already been seen with other COXIBs. For example,
using a model of peripherally induced inflammatory pain
(intraplantar injection of carrageenan) in rats, celecoxib
given systemically induced a state of hypoalgesia where
the (ipsilateral) nociceptive threshold was raised above
basal values. This effect was not observed after treat-
ment with non-selective inhibitors of COX (indometh-
acin, piroxicam). As naltrexone was able to reverse this
hypoalgesia, it was concluded that celecoxib could act
centrally via an effect mediated by endogenous opioids
rather than by inhibition of PG biosynthesis [26].Recently in rat, it was demonstrated that analgesic
central effects of celecoxib were prevented by selective
μ-(β-funaltrexamine) and δ-(naltrindole), but not ĸ-(nor-
binaltorphimine) opioid antagonists, after intracere-
broventricular administration [27]. This genuine effect of
COXIBs should deserve attention because cimicoxib
could have some advantages over non-COXIB NSAIDs to
treat some (chronic) conditions in which pain is unrelated
to inflammation.
The ultimate goal of the present experiment was to
assist in the selection of a dosage regimen for subse-
quent assessment in clinical trials. For this purpose,
dose-effect relationships were simulated using PK and
PD parameters obtained in the EM beagle dogs because
their PK parameters were closer to those of the four
non-beagle breed dogs. As explained in the result sec-
tion, our simulations assumed a linear disposition of
cimicoxib. However, the disposition of cimicoxib after an
oral administration was subsequently shown to be not
linear due to solubility saturation and the results of our
simulations should only be considered as indicative.
Visual examination of the simulated dose-responses
(from 0.1 to 8 mg/kg) with the various PD endpoints
(rectal temperature, creeping speed to cross a tunnel,
vertical ground reaction force of paw and clinical lame-
ness score), showed that a near-maximal effect was
obtained with a dose of 2 mg/kg for all effects but the
vertical force and that, above this dose, a further
increase was only able to increase the duration of the
cimicoxib effect. Visual inspection of the PK/PD simula-
tions clearly showed that a full pharmacological effect of
cimicoxib cannot be maintained over a 24 h dosage
interval with a single daily dose. However, it was consid-
ered that to split the daily dose was not in order given
that for other short acting COXIBs such as robenacoxib,
a once daily administration (1 mg/kg) was shown to be
clinically appropriate; Clinical trials with cimicoxib sup-
ported this interpretation (see later) and this is likely
due to the fact that our experimental model is more se-
vere that most of the clinical conditions encountered
and also to the likely longer persistence of the cimicoxib
in the synovial fluid of the target dog population as
already shown for robenacoxib [28]. Higher concentra-
tion of coxib and longer residence times in inflammatory
exudate compare to blood is likely a property of class
[1,29-31] and it is reasonable to assume that it is also
true for cimicoxib. To support this single cimicoxib daily
dose, the company carried out field trials on peri-
operative pain associated with orthopaedic or soft tissue
surgery using carprofen as a comparator (4 mg/kg per
day). Carprofen is as well-established NSAID with a half-
life of about 9 h in dogs [32], i.e. a half-life well-suited for
a single daily dose regimen. The non-inferiority of cimi-





























































































Figure 5 Observed ( ● ) and PK/PD predicted (−) effects of cimicoxib vs. time (h) after an oral administration of cimicoxib at 2 mg/kg
and observed ( ♦, ●●● ) effects of placebo vs. time (h) for 4 endpoints in a representative poor metabolizer dog. Predicted PK/PD effects
were obtain by fitting PD data using an indirect effect model (see Methods for details), for lameness score from 0 (no lameness) to 5 (maximal
lameness), see Figure 3 for a definition of the different scoring.
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score and a 20% difference as the inferiority limit [33]. For
the relief of pain and inflammation associated with osteo-
arthritis, the non-inferiority of cimicoxib against firocoxib
was also demonstrated with regard to the primary efficacy
endpoint and an inferiority limit set to 20% [34]. As cimi-
coxib administered once a day at a dose of 2 mg/kg was
shown not to be inferior to carprofen and firocoxib, two
drugs having a longer half-life than cimicoxib, the Euro-
pean Agency concluded that although PK/PD data indi-
cated that the duration of the effect was shorter than the
proposed dosing interval, this was regarded as acceptable,
given that appropriate information to this effect was in-
cluded in the product literature.Conclusions
Cimicoxib is an efficacious anti-inflammatory and anal-
gesic drug and thanks to a PK/PD approach, a rational
dosage regimen of 2 mg/kg was selected for confirma-
tory clinical trials allowing in fine the claim that cimi-




Twelve healthy Beagle dogs (6 females and 6 males)
were selected after clinical examination and biochemical
analysis to exclude any underlying pathologies. The
bodyweights and ages were 10 ± 2.5 kg and 1 ± 0.25 years,
respectively. The dogs were usually housed in large
boxes (2 per box). During the different periods of the
trial the animals were kept in individual stainless steel
cages in a controlled environment. Dogs were fed once a
day with 250 g of commercial dry food (Medium, Royal
Canin SA – Aimargues – France). On the day of the
trial, they were fed on the evening after the last mea-
surements. As the inflammatory model is totally revers-
ible without sequelae, all the dogs that participated in
this trial were rehomed as companion animals at the
end of the study.
Table 3 Pharmacodynamics parameters describing the cimicoxib effect after an oral administration of cimicoxib (2 mg/kg) in 4 poor metabolizers (PM) and 8
extensive metabolizers (EM) dogs




Kout (h-1) n (no unit)
PM EM PM EM PM EM PM EM PM EM PM EM












































































Parameters were estimated using indirect effect PK/PD models. Mean and range, Emax: maximum effect, EC50: plasma concentration to obtain 50% of the Emax, IC50: plasma concentration to obtain 50% of the Imax,




































































































































































Figure 6 Simulated values of the effects of the cimicoxib for different oral doses of cimicoxib for the 4 endpoints modeled using a
PK/PD model in the 8 extensive metabolizer dogs. Effects of cimicoxib vs. time (h) were simulated using the corresponding PK/PD model for
different oral doses of cimicoxib (from 0.1 to 8 mg/kg) on the rectal temperature (°C), the normalized vertical ground reaction force of the paw,
the creeping speed (m/s) and the overall clinical lameness score. PK and PD parameters used for simulations were the means of those obtained
in the 8 extensive metabolizer dogs. The thick line was obtained with 2 mg/kg, the dose that has been selected for confirmatory clinical trials.
Beyond this 2 mg/kg dose, the effects were not or marginally increased: the only consequence of the increase in the dose being to increase the
duration of the effect.
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Four different sized-breeds from four different private
breeders were tested (ten individuals were used from each
breed): Anglo-French Hounds, Pointers, Cavalier King
Charles Spaniels and Bernese Mountain Dogs. The body-
weights of the dogs ranged between [27.2, 37.4], [16.8,
22.3], [7, 9.8], [44.5, 62.5] kg; the ages were [0.6, 2.5], [1.9,
11.8], [1.7, 6.7], [1.4, 6.4] years for the Anglo-French
Hounds, Pointers, Cavalier King Charles Spaniels and
Bernese Mountain Dogs breeds, respectively. The sex
ratios (male/female) were 5/5, 6/4, 4/6 and 4/6 for these
same breeds. Prior to the experiment, all the animals
underwent a clinical examination by a veterinarian, along
with a complete biochemistry profile. No clinically import-
ant abnormality was noted during these examinations.
Animal care and conduct of the study were performed
according to the Guide for the Care and Use of LaboratoryAnimals. The protocol was approved by the animal
experimentation ethics committee of Midi-Pyrenees (MP/
01/41/09/08). The study was performed in compliance
with the Principles of Good Clinical Practice (CVMP/
VICH/595/98) and according to the Guideline for the




The 12 dogs were regularly trained to get accustomed to
experimental and measurements conditions for at least
one month before the beginning of the experiment.
Furthermore, all the investigators involved received a
special training for endpoints measurements. The paw
inflammation model used was the kaolin model (1.55 g











































Figure 7 Mean plasma concentrations (μg/mL) of cimicoxib vs. time in 4 different breeds after an oral administration of cimicoxib at
2 mg/kg. Mean values for 10 dogs per breed in 4 different breeds (Cavalier King Charles Spaniels, Pointers, Anglo-French Hounds and Bernese
Mountain). Visual inspection of the curves suggests differences between breeds likely due to differences in bioavailability.
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http://www.biomedcentral.com/1746-6148/9/250anesthesia, [15]). The measured endpoints used to evalu-
ate the antipyretic, analgesic and anti-inflammatory
effects of the NSAID were the body temperature, the
paw circumference, the time to perform a creeping test
under a tunnel, the lameness score, the vertical force of
the paw on force plates (normalized to the dog’s body
weight), the thermal pain threshold and the plantar skin
temperature [15]. For body temperature a single meas-
urement was obtained at each time using an electronic
thermometer. Paw circumference duplicate measures
per time point was done just above the pad using a
measuring tape (DMC, Colmar, France). Skin plantar
temperature was measured (in degrees Celsius) using an
infrared thermometer (Raynger M. Raytek, Fisher
Bioblock Scientific - Illkirch – France) at a reference site
on the plantar face of the paw, at six different times for
each day and measures were performed in triplicate.Table 4 Mean plasma half-life and other descriptive statistics
administration of cimicoxib at 2 mg/kg
Anglo-French hounds Pointers
Number of dogs 10 10
Minimum (h) 2.0 2.5
Maximum (h) 4.0 5.9
Mean (h) 3.2a,b 3.9a,c
Standard Deviation (h) 0.7 1
CV (%) 22.7 26.5
a,b,c : The values indexed by the same letter are not significantly different.Data used was the average of the three measurements per-
formed at each time point. Creeping time was measured
(in seconds) in a tunnel 6.38 m long, using a stopwatch
(digital stopwatch) in triplicate for each time point and
creeping speed (m/s) was used as the final measurement
for this endpoint. Lameness score was assessed using a
numerical rating scale as developed by Giraudel et al. [35].
Vertical normalized force i.e. the maximal vertical force
applied on the ground by a hind limb was measured with
force plates (SATEL Veto; Patrick Savet, Blagnac, France);
for each measurement time, three measures were recor-
ded, the mean values were normalized to the dog’s body
weight (Fmax/b.wt., kg/kg) and used in the data analyses.
Pain was assessed using a hind paw thermal escape model.
The model consisted of exposing the hind limb to a light
beam delivered by a Hargreaves apparatus (model 390;
IITC Inc., Woodlands Hills, CA) [13,36]. A heat intensityof cimicoxib in 4 dogs breeds after a single oral
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was selected. The paw withdrawal time (in seconds) was
measured. For each trial, three measures were recorded
per measurement time, and the mean of the three mea-
sures was used in the data analysis.
The study was conducted according to a classical 2×2
crossover design. Briefly, in period one, half of the dog
(3 males and 3 females), received a single oral dose
of cimicoxib (approximately 2 mg/kg, one 20 mg cap-
sules – Vetoquinol Lure france) 26.5 h after the induction
of kaolin inflammation on the left paw; the other half dogs
received a placebo treatment at the same time. In period
2, treatments were crossed over for each dog and inflam-
mation was induced on the right paw. A wash-out delay
of at least 5 weeks was applied between the two periods.
The treatment (cimicoxib or placebo) was blinded to the
investigators.
Blood samples (5 mL, heparinized tubes) were obtained
from the jugular vein by direct puncture just before
inflammation to perform a biochemical checkup of the
animals at the beginning of the experiment. Time 0 was
defined as the time of treatment administration. Blood
samples (5 mL, heparinized tubes) were collected at time 0
(just before cimicoxib or placebo administration) and then
at times 30, 60, 90 min, and, 4, 6, 9, 15, 30 and 48 hours
post-treatment. Tubes were centrifuged at 3000 G and
plasma samples were stored at −20°C.
At least three days before the induction of kaolin
inflammation, the PD endpoints were measured twice
on the same day to generate negative control values.
These endpoints were also measured at 23.5 and 25.5 h
after the induction of the inflammation (i.e. before the
treatment) to generate positive control values. Subse-
quently, the PD endpoints were measured at 2, 4, 9,
15 hours after administration (measures on all dogs) and
at 22 h and 27 h after administration depending on the
presence of further cimicoxib activity.
The results of this first study suggested that there
might be two subpopulations of dogs diverging in their
capacities to eliminate cimicoxib. To verify this hypoth-
esis, a PK investigation of cimicoxib following IV admin-
istration (bolus, 2 mg/kg) was performed on the 12 dogs
at least 2 months after the completion of the PK/PD
study. Blood samples were obtained from the jugular
vein by direct puncture at time 0 (control just before the
IV administration) and then 2, 15, 30, 60, 90 min. and 2,
3, 4, 6, 9, 12, 24, 30 and 48 hours after the test article
administration.
Study 2
The half-life of elimination of cimicoxib was studied in
four different sized breeds (40 dogs). Two mg/kg of
cimicoxib was administered orally, in the form of 10 and
20 mg (hard gelatin capsules, Vetoquinol). For each dog,four blood samples (5 mL, heparinized tubes) were
taken, at 6 h, 8 h, 10 h and 24 h after administration of
cimicoxib, centrifuged (3000 G) and stored (− 20°C).
Assay of cimicoxib in plasma
Plasma samples were analyzed by a High Performance
Liquid Chromatography (HPLC) method using ultraviolet
(UV) detection. Briefly, an internal standard (UR-8877)
and cimicoxib (UR-8880) were extracted from plasma by a
solid liquid (methanol) extraction process using HLB Oasis
cartridges (Waters). The extraction yield was about 90%.
The HPLC apparatus consists of a pump system equipped
with an automatic injector and an UV detector (242 nm).
Separation was achieved by reverse phase column with an
octadecylsilane stationary phase (Merck Lichrospher 100
RP18e (125×4) mm, 5 μm) using a guard column (Merck
Lichrospher 100 RP18e (4×4) mm, 5 μm). The mobile
phase was a mixture of 0.65 L of ultra-pure water and
0.35 L of acetonitrile which was delivered at a flow rate
of 1 mL per min. Under these conditions, cimicoxib
(UR-8880) and the internal standard (UR-8877) were
eluted at retention times of 6 to 7 min and 10 to 11 min,
respectively. The method was linear over the calibration
range of 0.01 to 5 μg/mL using a linear model weighted by
1/X2. Within-day and day-to-day coefficients of variation
were less than 9% and the accuracy ranged from 94 to
103%, indicating an appropriate precision and accuracy for
the analytical method. The lack of interference from en-
dogenous compounds was verified on blank plasma from
untreated dogs, establishing the specificity of the method.
The validated limit of quantification was 0.01 μg/mL.
Data analysis and modeling
Study 1
Pharmacokinetic and PK/PD modeling were performed
by least-squares regression analysis using WinNonlin
Professional software (WinNonlin® software, version
4.0.1, Pharsight Corporation, Mountain View, Ca, USA).
For PK analysis, individual plasma cimicoxib concentra-
tions were fitted to polyexponential equations. The data
points were weighted by the inverse of the squared-fitted
value. The number of exponential (2 or 3) terms needed to
obtain the best fit for each data set was determined by the
Akaike’s information criteria [37] and by inspecting the
plot of residuals. A biexponential equation corresponding
to a mono-compartmental model for extravascular admin-
istration with a lag-time was selected (Equation 1).
C tð Þ ¼ FDk01
V k01−k10ð Þ exp −k10  t−tlag
  
− exp −k01  t−tlag
 
ð1Þ
where C(t) is the cimicoxib plasma concentration (μg/L)
at time t (h), V/F (L/kg) is the apparent volume of
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ascending phase, k10 (1/h) the rate constant of the
terminal phase, tlag is the lag time and D is the cimicoxib
dose (mg/kg). The parameters (V/F, k01 and k10 and tlag)
were estimated.
For the IV study, a non-compartmental analysis was
used to determined PK parameters.
For PD analysis, a percentage of improvement was cal-
culated for all endpoints (except for the lameness score)
following Equation 2:





Where M is the measurement of the endpoint at
different times after administration of cimicoxib, T- is
the mean negative control value (before inflammation)
and T+ is the mean positive control value (after inflam-
mation but before any treatment).
The maximum effect was defined as the mean % of
improvement for a duration corresponding to a plateau
of effect as identified by the visual inspection of the
graph representing the % of improvement vs. time.
As the effect cimicoxib on the local temperature and
paw oedema after inflammation were present but lower
than the other effects, these endpoints were not used for
the PK/PD analysis. Similarly the analgesic effect was
discarded for modelling because it appeared to follow a
complicate pattern suggesting a dual mechanism of ac-
tion, namely an anti-nociceptive phenomenon and anti-
hyperalgesic one (see Discussion), requiring a more
advanced modelling with appropriate data that were not
available in this experiment. Finally, four endpoints were
considered as suitable for the PK/PD analysis aiming at
modelling the relationship between cimicoxib plasma
concentrations and its antipyretic and anti-inflammatory
effects, namely: body temperature (antipyretic effect),
creeping speed, vertical force of the paw and clinical
lameness score (anti-inflammatory effects).
The selected PK/PD models were of the class of the
indirect response models as proposed by Dayneka [38].
In these models, the measured response (R) is assumed
to result from factors controlling either the development
(Kin) or the dissipation (Kout) of the response according
to Equation 3.
dR
dt ¼ Kin−Kout  R= ð3Þ
where dR/dt is the rate of change of the response over
time, Kin represents the zero-order rate constant for
production of the response and Kout the first-order rate
constant for loss of the response. The time development
of measured response was modeled by a sigmoid-Emax
(maximum stimulatory effect) or sigmoid-Imax (maximum
inhibition effect) function (Hill models) that can be exertedeither on Kin or Kout. The parameters generated by such
analyses establishing the relationship between C(t), the
plasma drug concentration at time t, and the effect, are
the “Emax” or “Imax” for the drug effect (estimated max-
imum indirect effect), the “EC50” or “IC50” for the potency
(estimated plasma concentration which causes 50% of
Emax or Imax), and the Hill’s coefficient (n) for the sensi-
tivity of the different concentration-effect curves. The
effect of cimicoxib on the central temperature was
based on a model assuming that during the inflam-
mation phase, thermogenesis is increased (increase in
Kin) while thermolysis is reduced (reduction in Kout)
until a new balance for central temperature is reached.
The antipyretic effect of an NSAID consisted of an
increase in thermolysis (increase of Kout) enabling the
central temperature to return to its control values, accord-
ing to Equation 4:
dR
dT





For the creeping test consisting of crossing the tunnel
more or less rapidly, an empirical model postulating that
the dog’s speed (m.s-1) is the result of a balance between
its motivation to move forward (Kin) and a braking effect
(Kout) associated with the severity of inflammation with a
lower Kout in control conditions than during inflamma-
tion. During inflammation, pain increases the braking
effect (i.e. increase Kout) and decreases the speed to cross
the tunnel. The anti-inflammatory effect of cimicoxib
consisted in reducing the pain (by decreasing Kout), which
in turn increased the speed to cross the tunnel as des-
cribed by Equation 5:
dR
dT





For the vertical force measured with the force plate
apparatus normalized by the weight of the dog (without
units), Kin represents the ground reaction forces in con-
trol resting conditions and Kout represents the factors
prompting the withdrawal of limb from the ground in
the case of inflammation due to pain i.e. that Kout is
increased in the case of inflammation. Thus, the anti-
inflammatory effect of cimicoxib consisted in a reduc-
tion of pain (decrease of Kout) and the same model
as for the creeping speed under the tunnel was used
(see Equation 5).
For the clinical lameness score, an empirical model
was used postulating that the clinical score, from 0
(dog without lameness) to 5 (dog does not put limb
on the ground), was the result of a balance between
factors promoting lameness (Kin) and factors miti-
gating lameness (Kout). During inflammation, Kin is
increased and the effect of cimicoxib was modelled
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cording to Equation 6:
dR
dT




−Kout  R ð6Þ
Study 2
Half-life was estimated by log-linear regression (estimating
the slope) using the non-compartmental approach imple-
mented in Winnonlin.
Statistical analysis
Statistical analysis was carried out using Systat (Version
8.0, SPS Onc., Chicago, IL). For study 1, the comparison
between the two identified dog subpopulations for cimi-
coxib was done with an unpaired t-test. For study 2, the
effect of the breed on cimicoxib plasma half-life was
analyzed with a one-way ANOVA with the breed as
fixed effect factor.
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